Back to News
Market Impact: 0.1
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board
Source: marketbeat.com
Management & Governance
Cybin (NASDAQ: HELP), operating as Helus Pharma, held its Annual General and Special Meeting, with shareholders considering resolutions on the auditor, board size, corporate name and director elections. The article provides no voting outcomes, financial results or operational updates, limiting expected market impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
HELP0.00
More News
- Australia’s IDP shares drop after rejecting $494 mln Blackstone offer
- NYC Mayor Mamdani reaches record DoorDash settlement for underpaid workers
- CNN staffers panic over Paramount merger as layoffs loom in months ahead: ‘Bloodbath coming'
- McDonald's is hosting an investor day as its U.S. business struggles. Here are 4 things to expect
- 'War of the tech stacks': Paramount and WBD employees brace for internal competition after the merger closes
- Domo completes sale to Progress, rebrands as Huckleberry.ai